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ABSTRACT
Stabilization of stalled replication forks prevents ex-
cessive fork reversal or degradation, which can un-
dermine genome integrity. The WRN protein is unique
among the other human RecQ family members to
possess exonuclease activity. However, the biolog-
ical role of the WRN exonuclease is poorly defined.
Recently, the WRN exonuclease has been linked to
protection of stalled forks from degradation. Alter-
native processing of perturbed forks has been asso-
ciated to chemoresistance of BRCA-deficient cancer
cells. Thus, we used WRN exonuclease-deficiency as
a model to investigate the fate of perturbed forks un-
dergoing degradation, but in a BRCA wild-type con-
dition. We find that, upon treatment with clinically-
relevant nanomolar doses of the Topoisomerase I in-
hibitor camptothecin, loss of WRN exonuclease stim-
ulates fork inactivation and accumulation of parental
gaps, which engages RAD51. Such mechanism af-
fects reinforcement of CHK1 phosphorylation and
causes persistence of RAD51 during recovery from
treatment. Notably, in WRN exonuclease-deficient
cells, persistence of RAD51 correlates with elevated
mitotic phosphorylation of MUS81 at Ser87, which is
essential to prevent excessive mitotic abnormalities.
Altogether, these findings indicate that aberrant fork
degradation, in the presence of a wild-type RAD51
axis, stimulates RAD51-mediated post-replicative re-
pair and engagement of the MUS81 complex to limit
genome instability and cell death.
INTRODUCTION
The response to perturbed replication is crucial for the
maintenance of genome integrity (1–5). In humans, proper
handling of perturbed replication forks is also linked to can-
cer avoidance and many proteins involved in this process
act as onco-suppressors (3–6). The importance of correctly
dealing with perturbed replication forks is also demon-
strated by the existence of several human genetic diseases
caused by mutations in factors that sense, process and re-
cover replication forks (7).
The Werner’s syndrome protein (WRN) is one of these
key factors, and is mutated in the genetic disease Werner’s
syndrome (WS), which is characterized by cancer predispo-
sition and premature aging (8,9). From an enzymatic point
of view, WRN is both a DNA helicase and exonuclease;
however, while its helicase activity has been linked to pro-
cessing of reversed or collapsed replication forks (2,9), lit-
tle is known about the biological relevance of the exonu-
clease activity. Loss of WRN confers sensitivity to sev-
eral DNA-damaging agents inducing replication stress, in-
cluding Topoisomerase inhibitors (8,10,11). We recently re-
ported that the exonuclease activity of WRN is involved
in protecting replication forks perturbed by treatment with
the Topoisomerase I poison Camptothecin (CPT) in the
nanomolar range of concentration (12). Exposure to low
doses of CPT, as opposed to high doses, does not induce
DSBs but stimulates greatly formation of reversed forks
(13,14). Reversed replication forks are versatile yet vul-
nerable structures and several proteins participate in their
stabilisation (15–17). Two proteins, BRCA2 and RAD51,
are the most crucial for the stabilisation of reversed forks
(15,17,18). Thus, cells depleted of each of these two proteins
have been used as a prototypical model to assess the conse-
quences of inaccurate handling of reversed forks. However,
BRCA2 and RAD51 may also participate in DNA repair,
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which may be used to fix damage generated by fork insta-
bility (18–20). Cells expressing the exonuclease-dead WRN
retain ability to restart replication and are not overtly sensi-
tive to low doses of CPT, suggesting that alternative mecha-
nisms can be activated as a back-up. Since nanomolar doses
of CPT are clinically-relevant in cancer therapy, cells ex-
pressing a catalytically-inactive WRN exonuclease can be
used as a model to investigate the fate of CPT-perturbed
replication forks undergoing pathological degradation but
in a BRCA2-RAD51 wild-type background.
Here, we report that loss of WRN exonuclease channels
cells through a pathological RAD51-dependent mechanism
that makes perturbed replication forks resistant to breakage
upon prolonged exposure to nanomolar dose of CPT. Fur-
thermore, our data suggest that enhanced accumulation of
ssDNA and recruitment of RAD51 interfere with correct
activation of CHK1, which provides a positive feedback to
the formation of nascent ssDNA. Pathological engagement
of RAD51 makes WRN exonuclease-deficient cells depen-
dent on the mitotic function of theMUS81 complex to mit-
igate mitotic abnormalities deriving from accumulation of
RAD51-dependent intermediates.
MATERIALS AND METHODS
Cell lines and culture conditions
The SV40-transformed WRN-deficient fibroblast cell line
(AG11395) was obtained from Coriell Cell Reposito-
ries (Camden, NJ, USA). To produce stable cell lines,
AG11395 (WS) fibroblasts were transduced with retro-
viruses expressing the full-length cDNA encoding wild-type
WRN (WSWT), exonuclease-dead (WSE84A) or helicase-
dead (WSK577M) (21). All the cell lines were maintained
in Dulbecco’s modified Eagle’s medium (DMEM; Life
Technologies) supplemented with 10% FBS (Boehringer
Mannheim) and incubated at 37◦C in a humidified 5% CO2
atmosphere.
Plasmids transfection
Plasmid expressing the wild-type (Flag-CHK1WT) or the
phospho - mimic (Flag-CHK1S317/345D) mutant form of
CHK1, a kind gift from Professor K.K. Khanna (Queens-
land Institute of Medical Research, Australia) was gener-
ated as described (22). To express the plasmids, cells were
transfected using the Neon™ Transfection System Kit (In-
vitrogen), according to the manufacturer’s instructions.
Immunofluorescence assays
Cells were grown on 35-mm coverslips and harvested at
the indicated times after treatments. For RAD51 and
pS345CHK1 IF, after further washing with PBS, cells were
pre-extracted with 0,5% TritonX-100 and fixed with 3%
PFA/2% sucrose at RT for 10 min. After blocking in 3%
BSA for 15 min, staining was performed with rabbit mon-
oclonal anti-RAD51 or anti- pS345CHK1 diluted in a 1%
BSA/0.1% saponin in PBS solution, for 1 h at 37◦C in a
humidified chamber. For 53BP1, pS87MUS81, -tubulin,
Cyclin A, pS10H3 and pThr1989ATR staining, cells were
fixed with 4% PFA at RT for 10 min. Cells were subse-
quently permeabilized with 0.4% Triton-X100 and blocked
with 3% BSA. Staining with primary antibodies diluted in a
1% BSA/0.1% saponin in PBS solution was carried out for
1 h at 37◦ in a humidified chamber. After extensive washing
with PBS, specie-specific fluorophore-conjugated antibody
(Invitrogen) was applied for 1h at RT followed by counter-
staining with 0.5 mg/ml DAPI. Secondary antibody was
used at 1:200 dilution. Images were acquired as grayscale
files using Metaview software (MDS Analytical Technolo-
gies) and processed using Adobe Photoshop CS3 (Adobe).
For each time point, at least 200 nuclei were examined, and
foci were scored at 40×. Only nuclei with >5 foci were con-
sidered as positive and were quantified using ImageJ.
Antibodies
The primary antibodies used were: anti-pS345CHK1
(1:100, Cell Signaling Technologies), anti-pThr1989ATR
(1:100, GeneTex) anti-pS10H3 (1:1000, Santa Cruz
Biotechnologies), anti-Cyclin A (IF: 1:100, Santa Cruz
Biotechnologies), anti-53BP1 (1:300, Millipore), anti-
BrdU (1:50, Becton Dickinson; anti-IdU detection),
anti-pS87MUS81 (WB 1:1000, IF 1:200, Abgent),
anti-RAD51 (WB 1:1000, IF 1:100 Bioss Antibodies),
anti--Tubulin (1:50, Sigma-Aldrich), anti-Flag (1:1000,
Sigma-Aldrich) and anti-Lamin B1 (1:10000, Abcam).
HRP-conjugated matched secondary antibodies were from
Jackson Immunoresearch and were used at 1:20 000.
Chromatin fractionation and western blot analysis
Chromatin fractionation experiments were performed as
previously described (23). Western blotting was performed
using standard methods. Blots were incubated with pri-
mary antibodies against: rabbit anti-pCHK1(S345) (Cell
Signalling Technology), mouse anti-CHK1 (Santa Cruz
Biotechnology), rabbit anti-RAD51 (Bioss Antibodies),
mouse anti-RPA32 (Calbiochem), rabbit anti-RPA70
(GeneTex), mouse anti-GAPDH (Millipore) and rab-
bit anti-Lamin B1 (Abcam). After incubations with
horseradish peroxidase-linked secondary antibodies
(1:20 000, Jackson Immunosciences), the blots were
developed using the chemiluminescence detection kit
WesternBright ECL HRP substrate (Advansta) according
to the manufacturer’s instructions. Quantification was
performed on scanned images of blots using the Image Lab
software, and the values shown on the graphs represent
normalization of the protein content evaluated through
LaminB1 or GAPDH immunoblotting.
Clonogenic survival
Cells were plated onto 35 mm dishes, after 24 h they were
treated with different doses of CPT. After 18, cells were
washed, trypsinized and seeded in 60mm dishes. After 14–
21 days, plates were stained with crystal violet and colonies
counted.
Detection of nascent single-stranded DNA
To detect nascent single-strandedDNA (ssDNA), cells were
plated onto 22 × 22 coverslips in 35 mm dishes. After
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24 h, the cells were labeled for 15 min before the treat-
ment with 150 M IdU (Sigma-Aldrich), cells were then
treated with CPT 50 nM or 5 M for different time points.
Next, cells were washed with PBS, permeabilized with 0.5%
Triton X-100 for 10 min at 4◦C and fixed wit 2% sucrose,
3% PFA. For ssDNA detection, cells were incubated with
primary mouse anti-BrdU antibody (Becton Dickinson)
for 1 h at 37◦C in 1% BSA/0.1% saponin, followed by
Alexa Fluor488-conjugated goat-anti-Mouse (Invitrogen),
and counterstained with 0.5 g/ml DAPI. Slides were an-
alyzed with Eclipse 80i Nikon Fluorescence Microscope,
equipped with a VideoConfocal (ViCo) system. For each
time point, at least 100 nuclei were scored at 40×. Paral-
lel samples either incubated with the appropriate normal
serum or only with the secondary antibody confirmed that
the observed fluorescence pattern was not attributable to
artefacts. Fluorescence intensity for each sample was then
analyzed using ImageJ software.
Statistical analysis
All the data are presented as means of at least two inde-
pendent experiments. Statistical comparisons of WSWT or
WRN-mutant cells to their relevant control were analyzed
by ANOVA or Mann–Whitney test. P < 0.05 was consid-
ered as significant.
RESULTS
Loss of WRN exonuclease activity leads to a persisting and
unusual formation of nascent ssDNA which compromises for-
mation of DSBs in response to a low-dose of camptothecin
Treatment with nanomolar concentrations of CPT does not
induce DSBs immediately but stimulates fork reversal (13).
Under such conditions, loss of WRN exonuclease activ-
ity results in the rapid (<2 h) degradation of both nascent
strands by theMRE11-EXO1 nucleases (12). In this regard,
WRN exonuclease deficiency is a useful model to determine
what happens to nuclease-targeted forks after prolonged
treatment with a low dose of CPT in a genetic background
retaining BRCA2-RAD51 function.
We first examined the accumulation of nascent ssDNA
as a sign of fork degradation by the native IdU assay. In
order to track accumulation of fork processing events with
time, we used continuous labeling of nascent DNA and
analyzed formation of ssDNA at forks beyond the 2 h of
treatment already explored on CPT (Figure 1A; (12)). As
expected, WS cells expressing the exo-dead WRN protein
(WSE84A) showed less nascent ssDNA then the corrected
wild-type counterpart (WSWT) at 1 h of treatment (Figure
1A). Surprisingly, while the amount of nascent ssDNA in-
creased only slightly in cells expressing the wild-typeWRN,
it accumulated greatly over time in WRN exonuclease-
deficient cells and largely exceeded the wild-type level at
4 h (Figure 1A). Of note, the excessive nascent ssDNA for-
mation detected at 4 h of CPT was recapitulated also in
doxycycline-inducible shWRNcells complementedwith the
RNAi-resistant WRNE84A or the WRNK577M-E84A mutant,
which contains mutations disabling both the helicase and
the exonuclease activities (Supplementary Figure S1A, B).
These results indicate that the observed phenotype is cell
line-independent and does not derive from uncoordinated
action of helicase and exonuclease activities of WRN. The
enhanced accumulation of nascent ssDNA was also inde-
pendent on any difference in the expression of exo-dead
WRN compared to the wild-type (12). Indeed, overexpres-
sion of the exo-dead WRN induced aberrant accumulation
of ssDNA also in the inducible shWRN cells cultured in
the absence of doxycycline (Supplementary Figure S2A, B).
Finally, the aberrant accumulation of nascent ssDNA in
WSE84A cells was specific of the response to a low-dose of
CPT, as treatment with HU or a high-dose of CPT failed to
recapitulate the phenotype (Supplementary Figure S3).
Interestingly, when the formation of nascent ssDNA was
evaluated using the same labeling scheme used previously
inWSE84A cells (Supplementary Figure S4A; (12)), a bipha-
sic curve was clearly apparent (Supplementary Figure S4B).
The biphasic curve of ssDNA accumulation after CPT
showed an initial increase followed by a drop, consistently
with previous data (12), and a subsequent significant in-
crease at the late time-point (Supplementary Figure S4B).
This suggests that extensive degradation is maintained over
the entire duration of treatment. Furthermore, time-course
analysis of the nascent ssDNA formation by the native IdU
assay confirmed that Mirin treatment decreases nascent ss-
DNA exposure early after CPT exposure, while increases
ssDNA formation at 4h in WSE84A cells (Supplementary
Figure S4C, D), suggesting that late formation of nascent
ssDNA occurs through a distinct mechanism.
Since nascent strand degradation is MRE11-dependent
in the absence of the WRN exonuclease while it is DNA2-
dependent in wild-type cells (12,24), we next examined if
chemical inhibition of the two nucleases might reduce the
idiosyncratic accumulation of ssDNA detected at 4h of
treatment in WSE84A cells. Mirin treatment barely reduced
ssDNA detected at 4 h of treatment in wild-type cells (Fig-
ure 1B). Surprisingly, Mirin did not decrease the formation
of ssDNA inWRN exonuclease-deficient cells but rather in-
creased it even further (Figure 1B). Inhibition of DNA2 by
the small-molecule inhibitor C5 (25) increased formation of
nascent ssDNA in wild-type but not in WRN exonuclease-
deficient cells (Figure 1B). In contrast, concomitant inhi-
bition of DNA2 and MRE11 was ineffective in modulat-
ing nascent ssDNA formation in wild-type cells while de-
creased its level in WSE84A cells (Figure 1B). Of note, ss-
DNA derived from end-resection of DSBs induced by a mi-
cromolar dose of CPT was efficiently reduced by DNA2
inhibitor C5 (Supplementary Figure S5A, B), providing a
functional proof of the inactivation of the nuclease activ-
ity in our cell model. Depletion of MRE11 or DNA2 by
specific siRNA (Supplementary Figure S6A, C) confirmed
that, in WSE84A cells, nascent ssDNA was increased when
MRE11, but not DNA2, is defective (Supplementary Fig-
ure S6B, D). Of note, however, depletion of EXO1 substan-
tially reduced the accumulation of nascent ssDNA at 4 h of
CPT, almost restoring the wild-type levels (Supplementary
Figure S7A, B). These results indicate that different sets of
nucleases are involved in the degradation of nascent ssDNA
in WRN exonuclease-deficient cells when treatment is pro-
longed.
DNA breakage can occur even in response to low-doses
of CPT if treatment is sufficiently prolonged (13,14). Thus,
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Figure 1. Loss of WRN exonuclease activity leads to formation of nascent ssDNA which compromises formation of DSBs in response to a low-dose of
camptothecin. (A) Evaluation of ssDNA by anti-IdU immunofluorescence under non-denaturing condition. Nascent DNAwas pre-labeled for 15 min with
IdU before treatment and labeling remained during treatment with CPT. Dot plots show the mean intensity of ssDNA staining for single nuclei from cells
expressing the wild-type (WSWT) or the exo-dead form of WRN (WSE84A). Cells were either left untreated or challenged with 50 nM CPT for increasing
periods, as indicated. The intensity of the anti-IdU immunofluorescence was measured in at least 200 nuclei from three independent experiments. Values are
represented as means±SE. Representative images of ssDNA labeling are shown. (B) Evaluation of nascent ssDNA in cells treated with nuclease inhibitors.
Cells were treated withMirin, C5 or both 30 min before IdU labeling and 45 min before CPT treatment for 4 h, and then subjected to the ssDNA assay. The
graph shows the mean intensity of IdU fluorescence measured from two independent experiments (n = 200), data are presented as mean ± SE. Statistical
analysis in A and B was performed by the Mann–Whitney test (**P < 0.01; ***P < 0.001; ****P < 0.0001). (C) Analysis of DSB accumulation by the
neutral Comet assay. Cells were treated or not with CPT 50 nM for the indicated time, or with 5M CPT (high-dose) for 1 h, and then subjected to the
neutral Comet assay. Where indicated, cells were pre-treated with Mirin, C5 or both. In the graph, data are presented as mean tail moment ± SE from two
independent experiments (ns = not significant; **P < 0.01; ***P < 0.001; ****P < 0.0001; ANOVA test). Representative images from the neutral Comet
assay are shown.
to further investigate the origin of the late nascent ssDNA
in the WRN exonuclease-deficient cells and the role of the
different nucleases, we analyzed the presence of DSBs after
treatment with nanomolar CPT by neutral Comet assay. As
shown in Figure 1C, treatment with 50nM CPT for 4 h in-
duced some DSBs in wild-type cells, although they are very
low compared with those generated by the 5M reference
dose and were not dependent on MUS81 (Supplementary
Figure S5C). In contrast, no DSBs were detected in WRN
exonuclease-deficient cells after treatment with a low-dose
of CPT, even if they were readily seen in response to a high-
dose of the drug (Figure 1C).
Interestingly, pre-treatment with Mirin, which enhances
ssDNA in WSE84A cells (Figure 1B), resulted in DSBs
(Figure 1C). In contrast, Mirin or the DNA2 inhibitor
C5 decreased formation of DSBs in wild-type cells, alone
or as a combination (Figure 1C). Interestingly, inhibi-
tion of both MRE11 and DNA2, which decreases ssDNA
formation in WSE84A cells (Figure 1B), significantly re-
duced DSBs generated by Mirin also in the mutant cells
(Figure 1C).
Collectively, our results indicate that loss of theWRN ex-
onuclease leads to accumulation of nascent ssDNA when
treatment with nanomolar CPT is prolonged beyond 2 h
and that it makes cells refractory to formation of DSBs by
CPT. Our data also suggest that the late accumulation of
nascent ssDNA in WSE84A cells is related to the activity of
multiple nucleases.
Loss of WRN exonuclease stimulates engagement of RAD51
after CPT-induced fork perturbation
In WRN exonuclease-deficient cells, the late reappearance
and accumulation of nascent ssDNA together with loss of
DSBs might correlate with engagement of an alternative or
aberrant fork processing mode over time after CPT. Since
extended regions of ssDNA are a substrate of RAD51 dur-
ing recombination, we investigated whether loss of WRN
exonuclease could affect recruitment of RAD51.
We first evaluated recruitment of RAD51 in chromatin
using biochemical fractionation and western blotting. In
wild-type cells, RAD51 barely increased its chromatin asso-
ciation after CPT treatment (Figure 2A). Expression of the
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Figure 2. Loss of WRN exonuclease stimulates engagement of RAD51 af-
ter CPT. (A) WB analysis of chromatin association of RAD51 and RPA32
in wild-type (WSWT) and in cells expressing the exo-dead mutant form of
WRN (WSE84A). Cells were treated or not with CPT for 4 h. LaminB1
was used as loading control. The blot is representative of three replicates.
The graphs show the quantification of the amount of RAD51 or RPA32
normalized against LaminB1 (mean ± SE). (B) Quantitative immunoflu-
orescence analysis of RAD51 foci in WSWT and WSE84A cells. Cells were
treated with CPT 50 nM for 4 h, triton-extracted and subjected to RAD51
immunostaining. Graph shows the intensity of RAD51 immunostaining
for each cell with scorable foci (n > 3). Values are presented as means ±
SE (***P < 0.001; ****P < 0.0001; Mann–Whitney test). Representative
images are shown.
exo-deadWRN, however, greatly heightened the amount of
RAD51 in chromatin already in untreated cells and treat-
ment with CPT led to a minimal increase over untreated
(∼20%; Figure 2A). As a control, we alsomeasured the level
of RPA32 in chromatin. RPA32 is a subunit of the RPA
heterotrimer that binds to ssDNA competing with RAD51.
Chromatin-bound RPA32 increased in wild-type cells af-
ter CPT (Figure 2A). In contrast, the amount of RPA32 in
chromatin was low in the absence of the WRN exonucle-
ase and did not show any increase after treatment (Figure
2A). Immunofluorescence analysis of RPA32 recruitment
in nuclear foci confirmed the reduced chromatin localisa-
tion of RPA in the WSE84A cells and evidenced a significant
decrease in the fraction of RPA32 phosphorylated at S33
(Supplementary Figure S8A, B).
RAD51 participates in multiple pathways (26,27) and
chromatin recruitment may reflect such pleiotropy of roles.
To further verify the increased recruitment of RAD51 in
cells expressing the exo-dead WRN, we performed a quan-
titative immunofluorescence analysis of the RAD51 foci,
which reflects formation of RAD51 nucleofilaments (Fig-
ure 2B). Consistent with biochemical data, loss of WRN
exonuclease increased recruitment of RAD51 in foci (Fig-
ure 2B). Moreover, CPT treatment led to a further en-
hancement of RAD51 foci in WRN exonuclease-deficient
cells compared with the wild-type (Figure 2B). Increased
recruitment of RAD51 in chromatin was also observed
when the exo-dead WRN was added-back to doxycycline-
inducible shWRN cells but not in cells complemented with
the wild-type WRN (Supplementary Figure S9). The op-
posed behavior of RAD51 and RPA chromatin association
in WSE84A cells was specific for a low-dose of CPT since it
was not detected in response to HU or micromolar CPT
(Supplementary Figure S10A). Most notably, BRCA2 de-
pletion abrogated the recruitment in chromatin of RAD51
in WSE84A cells (Supplementary Figure S10B).
The biphasic nature of ssDNA accumulation observed in
the absence of WRN exonuclease activity in cells treated
with a low-dose of CPT prompted us to investigate on the
kinetics of replication fork recruitment of the mutantWRN
protein by the EdU-PLA technique (SIRF; (28,29)). After
a pulse-labeling of nascent DNA with EdU, wild-type cells
or cells expressing the exo-dead WRN, were treated with
CPT and tested for the association of WRN with EdU-
labeled nascent DNA by proximity-ligation assay in situ
(Figure 3A). The catalytically-active WRN showed a no-
ticeable fork recruitment already at 1 h of CPT treatment,
which increased further and significantly at 4 h (Figure 3B).
As expected by our previous data (12), the exo-dead WRN
was less fork-associated than the wild-type at the early time-
point but surprisingly increased its fork association at 4 h
reaching the wild-type value (Figure 3B).
These results suggest that, in the absence of theWRN ex-
onuclease, RAD51 takes over RPA and the normal mecha-
nism handling CPT-perturbed replication forks. Moreover,
our results also indicate that recruitment of exo-deadWRN
at perturbed forks is delayed early but is enhanced at 4h of
treatment when the level of nascent ssDNA elevates accord-
ingly.
Loss of WRN exonuclease stimulates the persistence of
under-replicated DNA and RAD51 accumulation during re-
covery from low-dose of CPT
To determine if the increased RAD51 recruitment could
correlate with recovery from replication fork perturbation,
we analyzed RAD51 chromatin levels after CPT with-
drawal. To this end, we treated cells with CPT and allowed
them to recover for 2 and 4 h before analyzing chromatin
fractions. As shown in Figure 4A, while RAD51 chromatin
levels were consistently low during recovery in wild-type
cells, they were still elevated in WRN exonuclease-deficient
cells. In contrast, the amount of chromatin-bound RPA32
and RPA70, two subunits of trimeric RPA, was low in
WSE84A cells during recovery while it increased greatly in
cells expressing the wild-type WRN (Figure 4A). To con-
firm this result, we performed quantitative immunofluores-
cence analysis of the formation of RAD51 foci. A reduction
of RAD51 foci was observed during recovery from CPT in
wild-type cells while the number of RAD51 foci increased
in WRN exonuclease-deficient cells (Figure 4B).
Inhibition of MRE11 and DNA2 restores wild-type lev-
els of nascent ssDNA in WRN exonuclease-deficient cells
(Figure 1C). To determine if the persistence of chromatin-
bound RAD51 in WSE84A cells during recovery correlates
with the accumulation of nascent ssDNA occurring dur-
ing treatment, we analyzed RAD51 focus-forming activity
in cells exposed to CPT and to the two nuclease inhibitors
Mirin and C5. As expected, RAD51 recruitment in foci was
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Figure 3. WRN recruitment at CPT-perturbed replication forks is delayed in WSE84A cells. (A) Analysis of WRN fork recruitment by in situ EdU-PLA.
Cells were treated as indicated in the schemes. (B) The graph shows the number of PLA spots per cell. Values are presented as means ± SE (ns, not
significant; *P < 0.05; ***P < 0.001; ****P < 0.0001; Mann–Whitney test). Representative images are shown.
elevated inWRN exonuclease-deficient cells after treatment
and even more during recovery (Figure 4C). Interestingly,
however, treatment with C5 and Mirin before CPT signif-
icantly reduced the persistence of RAD51 foci in WSE84A
cells during recovery (Figure 4C).
The elevated levels of RAD51 during recovery might be
related to the presence of under-replicated DNA that en-
gages recombination to be repaired or fully replicated (30).
Thus, we analyzed whether cells recovering fromCPT treat-
ment presented under-replicated regions of DNA. Since
under-replication is expected to leave regions of ssDNA
behind perturbed forks in the parental strand (parental
gaps), we performed native ssDNA assay after a 24 h treat-
ment with IdU to label all parental DNA (Figure 4D). As
shown in Figure 4E, little parental ssDNA was detectable
in wild-type cells after treatment and its amount decreased
substantially during recovery. In WSE84A cells, however,
parental ssDNA was increased at the end of treatment and
remained elevated during recovery (Figure 4E). Interest-
ingly, the increased amount of parental ssDNA paralleled
that of RAD51 foci, suggesting that RAD51 may be re-
cruited to deal with under-replicated regions. Both pheno-
types observed in WSE84A cells during recovery were reca-
pitulated in the doxycycline-inducible shWRN cells after
complementation with the exo-deadWRN (Supplementary
Figure S11A–C). Of note, persistence of parental gaps was
not related to repair of the poisonedCPT since it was not af-
fected by depletion of TDP1 (Supplementary Figure S12A,
B).
Collectively, these results indicate that loss of WRN ex-
onuclease results in persistence of parental gaps DNA dur-
ing recovery, which correlates to increased RAD51 recruit-
ment. Furthermore, our data suggest that persistence of
parental gaps and increased RAD51 during recovery is a
consequence of the late accumulation of nascent ssDNA.
Loss of WRN exonuclease reduces activation of CHK1
Our data indicate that loss of the WRN exonuclease re-
sults in accumulation of ssDNA and RAD51 accompa-
nied by a concomitant decrease of RPA and pS33RPA32 in
chromatin. Since RPA-coated ssDNA is required for check-
point signaling upon replication fork perturbation, we in-
vestigated whether the functionality of the WRN exonu-
clease might also affect activation of the replication check-
point in response to nanomolar concentration of CPT. As
a readout of the activation of the ATR-dependent check-
point response, we analyzed phosphorylation of CHK1 at
S345 by western blotting. In wild-type cells, treatment with
a nanomolar dose of CPT induced a time-dependent phos-
phorylation of CHK1 which is also readily observed in
cells expressing the helicase-dead form ofWRN (WSK577M)
(Figure 5A). In contrast, CPT-induced phosphorylation of
CHK1was reduced in cells expressing the exonuclease-dead
mutant of WRN, and this phenotype was more evident at
4 and 6h of treatment (Figure 5A). The requirement of the
WRN exonuclease for correct CHK1 phosphorylation was
specific for the low-dose CPT treatment as it was not ob-
served after 5M of CPT (Supplementary Figure S13A).
To confirm that loss ofWRNexonuclease affectedCHK1
phosphorylation by an independent assay, we monitored
the status of S345 of CHK1 by immunofluorescence. As
shown in Figure 5B and D, a reduced phosphorylation of
CHK1 at S345 was readily detected also by immunofluo-
rescence in WRN exonuclease-deficient cells.
Next, we wanted to analyze whether decreased activa-
tion of CHK1 correlated with reduced activation of ATR-
dependent signaling. To assess activation of ATR, we mon-
itored phosphorylation of the activating site T1989 by im-
munofluorescence. Despite the defective phosphorylation
of CHK1, ATR was phosphorylated similarly in wild-type
cells and in cells expressing the exonuclease-dead form of
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Figure 4. RAD51 recruitment persisted during recovery from CPT in the absence of the WRN exonuclease. (A) WB analysis of chromatin association of
RAD51, RPA70 and RPA32 in wild-type (WSWT) and in cells expressing the exo-dead mutant form of WRN (WSE84A). Cells were treated or not with
50 nM CPT for 4h followed by recovery as indicated. LaminB1 was used as loading control. The blot is representative of three replicates. The graphs
show the quantification of the amount of RAD51 or RPA32 normalized against LaminB1 (mean ± SE). (B) Quantitative immunofluorescence analysis
of RAD51 foci in WSWT and WSE84A cells. Cells were treated with CPT 50nM for 4 h and recovered or not as indicated. Graph shows the intensity of
RAD51 immunostaining for each cell with scorable foci (n > 3). Values are presented as means ± SE (***P < 0.001; **** P < 0.0001; Mann–Whitney
test). Representative images are shown. (C) Quantitative immunofluorescence analysis of RAD51 foci in WSWT and WSE84A cells pre-treated with the
nuclease inhibitors. Cells were pre-treated with the indicated inhibitors prior to be challenged with CPT 50nM for 4h and recovered or not as indicated.
Graph shows the intensity of RAD51 immunostaining for each cell with scorable foci (n > 3). Values are presented as means ± SE (**P < 0.01; ****P <
0.0001; Mann–Whitney test). (D, E) analysis of parental ssDNA. Parental DNA was labeled with IdU as indicated in the experimental scheme (D). (E)
The graph shows the amount of parental ssDNA calculated as mean intensity of IdU fluorescence measured from two independent experiments (n= 200),
data are presented as mean ± SE. Statistical analysis was performed by the Mann–Whitney test (**P < 0.01; **** P < 0.0001). Representative images are
shown.
WRN (Figure 5C, D). Since loss of WRN exonuclease af-
fects recruitment of RPA but did not affect activation of
ATR, we analyzed whether it could influence recruitment
of other factors modulating ATR-checkpoint function. As
loss of WRN exonuclease leads to accumulation of nascent
ssDNA at 4h of CPT (Figure 1A), we analyzed the pres-
ence of TopBP1 and RAD9, which associates with TopBP1
(31,32), specifically at nascent ssDNA by our recently de-
scribed IdU-PLA assay (12). In parallel, we evaluated the
presence of the total amount of ssDNA by IdU assay. As-
sociation of TopBP1 or RAD9 with nascent ssDNA was
not detected under untreated conditions (data not shown),
however, treatment with 50nM CPT for 4h resulted in re-
cruitment of both factors at nascent ssDNA in wild-type
cells (Figure 5E, F). Of note, loss of WRN exonuclease re-
duced the recruitment of TopBP1 but not that of RAD9 at
the nascent ssDNA (Figure 5E, F) although in these condi-
tions the IdU assay detected 2-times more ssDNA (Figure
5G).
Loss of the WRN exonuclease leads to accumulation
of nascent ssDNA, which is targeted by RAD51 and
not by checkpoint factors, possibly resulting in reduced
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Figure 5. Loss of WRN exonuclease activity affects phosphorylation of CHK1. (A) WB analysis of CHK1 phosphorylation at S345 in wild-type (WSWT)
and in cells expressing the exo-dead mutant form of WRN (WSE84A) or the helicase-dead form (WSK577M). Cells were treated or not with 50nM CPT
as indicated. Total CHK1 and GAPDH were used as loading controls. The blot is representative of three replicates. Below is reported quantification
of pS345CHK1 phosphorylation normalized against total CHK1. (B) Immunofluorescence analysis of pS345CHK1 in WSWT and WSE84A cells treated
with CPT 50nM for 4 h. Numbers in insets represent the mean percentage of pS345CHK1-positive nuclei (n = 2). (C) Immunofluorescence analysis of
pT1989ATR in WSWT andWSE84A treated with CPT 50nM for 4 h. Numbers in insets represent the mean percentage of pS345CHK1-positive nuclei (n=
2). (D) Quantification of the anti-pS345 and pT1989ATR IF. (E-F) Analysis of TopBP1 or RAD9 recruitment at nascent ssDNA by PLA. Nascent strand
was labeled with IdU for 15 min before cells were treated with 50nM CPT for 4 h. PLA was performed under native conditions using anti-IdU to detect
nascent ssDNA and anti-TopBP1 or RAD9 to detect the protein. Negative controls are from samples processed with anti-IdU only. The graphs show the
number of PLA spots in each nucleus (n= 300 from three independent replicates). Statistical analysis was performed by the Mann–Whitney test (ns = not
significant; ****P < 0.0001). Representative images are shown. (G) Duplicated samples from D and E were analyzed for the presence of nascent ssDNA
by native anti-IdU detection only. The graph shows the mean intensity of IdU fluorescence measured from two independent experiments (n = 200), data
are presented as mean ±SE. Statistical analysis was performed by the Mann–Whitney test (***P < 0.001).
CHK1phosphorylation. Thus, we investigatedwhether pre-
treatment with the RAD51 inhibitor B02 or could re-
establish a normal CHK1 activation in WRN exonuclease-
deficient cells (Supplementary Figure S13B). Of note, in-
hibition of RAD51 further decreased the phosphorylation
of CHK1 regardless the way it was added (Supplemen-
tary Figure S13B). This was surprising but prompted us
to evaluate whether reduced CHK1 activation could be im-
plicated in the enhanced accumulation of nascent ssDNA.
To test this potential feedback effect, we over-expressed
the S317/S345D CHK1 phosphomimetic mutant (22) in
WSE84A cells before evaluating the formation of nascent
ssDNA by the IdU assay (Figure 6A). As shown in Fig-
ure 6B, the phosphomimetic CHK1 and the wild-type form
were efficiently over-expressed in the cells, however, only the
phosphomimetic CHK1 mutant was able to substantially
reduce the amount of nascent ssDNA inWRNexonuclease-
deficient cells restoring the wild-type levels, while overex-
pression of the wild-type increased further the amount of
nascent ssDNA.
Altogether, our results show that loss of WRN exonucle-
ase activity affects proper activation of CHK1 in response
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Figure 6. Expression of a phosphomimic CHK1 mutant restores wild-
type levels of nascent ssDNA in WRN exonuclease-deficient cells. (A)
WB analysis of FLAG-CHK1WT and FLAG-CHK1S317/345D expression
inWSE84A cells. (B) Evaluation of nascent ssDNA formation. Cells treated
with 50nM CPT for 4 h were analyzed for the presence of nascent ssDNA
by native anti-IdU detection. The graph shows the mean intensity of IdU
fluorescence measured from two independent experiments (n = 200), data
are presented as mean ± SE. Statistical analysis was performed by the
Mann–Whitney test (*P < 0.05; ***P < 0.001; ****P < 0.0001). Repre-
sentative images are shown.
to a low-dose of CPT and that reduced phosphorylation
of CHK1 probably correlates with reduced recruitment of
checkpoint factors at ssDNA. They also suggest that re-
duced CHK1 phosphorylation contributes to the accumu-
lation of ssDNA in the nascent strand, possibly as part of a
positive feedback loop.
WRN exonuclease-deficient cells need the mitotic function of
MUS81 to counteract mitotic aberration andmis-segregation
Inaccurate processing of perturbed replication forks, under-
replicated DNA and elevated RAD51 levels observed in the
absence of WRN exonuclease could threaten mitosis be-
cause of DNA interlinking as reported in BRCA2-deficient
cells (33). Mitotic resolution of DNA interlinked interme-
diates involves the MUS81/EME1 complex (34,35). Thus,
we evaluated whether WRN exonuclease-deficient cells ac-
cumulated active MUS81 in mitosis by performing im-
munofluorescence with an antibody directed against the
pS87-MUS81, which we have demonstrated to mark the ac-
tive MUS81/SLX4 complex (36). In wild-type cells, little
MUS81 phosphorylation at S87 was detectable under un-
perturbed cell growth or in response to low-dose of CPT
(Figure 7A). In contrast, many pS87-MUS81-positive nu-
clei were observed in cells expressing the exonuclease-dead
WRN already in unperturbed conditions (Figure 7A). No-
tably, in WRN exonuclease-deficient cells, pS87-MUS81
levels were further enhanced by CPT and remained elevated
also after recovery (Figure 7A). Interestingly, and consistent
with our previous results (36), phosphorylation of MUS81
never occurred in EdU-labeled S-phase cells (Figure 7A).
To determine if under-replication and enhanced RAD51
recruitment correlates with elevated MUS81 activation,
we asked whether treatment with B02 (37) reverted the
pS87-MUS81 levels inWRN exonuclease-deficient cells. As
shown in Figure 7B, inhibition of RAD51 greatly reduced
pS87-MUS81-positive nuclei after recovery from CPT in
the absence of the WRN exonuclease activity.
Enhanced activation of MUS81 in mitosis might be in-
dicative of persistence of unresolved DNA intermediates
in WSE84A cells, which could induce mitotic abnormali-
ties or segregation defects. To assess if loss of WRN ex-
onuclease could result in segregation defects, we first an-
alyzed the presence of bulky anaphase bridges in DAPI-
stained cells (Figure 7C). Interestingly, anaphase cells were
highly enriched inWRN exonuclease-deficient cells (Figure
7C; see numbers above the bars), suggesting that these cells
may experience a delayed exit from anaphase. However, the
number of anaphases with bridges was very low in WRN
exonuclease-deficient cells as compared to the wild-type
(Figure 7C). Since delayed exit from anaphase might de-
rive frommitotic defects and could result in post-mitotic ab-
normalities, we decided to evaluate the presence of aberrant
mitoses, multinucleated cells and micronuclei. As shown in
Figure 7D, we found that both aberrant mitosis and cells
with micronuclei were increased in WSE84A cells. In con-
trast, no difference in multinucleated cells was found be-
tween cells expressing wild-type or exo-dead WRN (Figure
7D).
The presence of under-replicated DNA or the persis-
tence of unresolved DNA intermediates in G2/M triggers
the formation of 53BP1 NBs in the subsequent G1 phase
(38). Since WRN exonuclease-deficient cells showed per-
sistence of under-replicated DNA, we investigated whether
they accumulated 53BP1 NBs. To this end, we performed
immunofluorescence against 53BP1 and CyclinA in cells
recovering from 4h of treatment with CPT and scored
the number of 53BP1 NBs-positive cells in the CyclinA-
negative population (i.e. G1 cells). As shown in Figure 7E,
the number of 53BP1 NBs in WSE84A cells was higher than
in wild-type cells even in untreated conditions. Treatment
with CPT enhanced the number of 53BP1 NBs in wild-type
and in WRN exonuclease-deficient cells; however, the in-
crease was substantially higher in cells expressing the exo-
dead WRN (Figure 7E and Supplementary Figure S14).
Notably, inhibition of RAD51 in WRN exonuclease-
deficient cells resulted in persistent accumulation of mitotic
cells in pro-metaphase (Supplementary Figure S15). This
result suggested that loss of RAD51 undermines correct
mitotic progression inWRN-exonuclease-deficient cells but
prevented assessment of any correlation between enhanced
engagement of RAD51 and mitotic defects or formation of
53BP1 NBs.
In WRN exonuclease-deficient cells engagement of
RAD51 is functionally related to elevated levels of S87-
MUS81 phosphorylation (Figure 7B). Thus, we next an-
alyzed whether inactivation of the mitotic function of
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Figure 7. WRN exonuclease-deficient cells show enhanced MUS81 phosphorylation on S87 and mitotic defects. (A) Anti-pS87MUS81 immunofluores-
cence staining (red) was performed in wild-type andWRN exonuclease-dead expressing cells. The S-phase cells (green) were revealed with short EdU pulse
followed by Click-IT reaction. Nuclei were depicted with DAPI staining (blue). The mean frequency (±SE; n = 3) of pS87-MUS81-positive nuclei are
indicated in the representative images. (B) WS cells expressing the WSE84A mutant were treated with CPT for 4h and then released in fresh medium for 18
h. The RAD51 inhibitor B02 was added with CPT and during the recovery. The frequency (±SE; n = 2) of pS87-MUS81-positive nuclei are indicated as
percentage in the representative images. (C) The graph shows the mean percentage ± SE of bulky anaphase bridges analyzed in untreated and CPT-treated
cells expressing WRN wild-type and the exonuclease-deficient mutant. The number of anaphases counted for each experimental point are indicated above
as n. Randomly-selected representative anaphases with bridges are shown. (D) Representative images of mitotic aberrations analyzed in -Tubulin (green)
and DAPI-stained cells are shown above the graph indicating the frequency of each event after treatment with 50nM of CPT for 4h followed by a 18 h
recovery. Data are presented as mean ± SE. Statistical analysis was performed by the ANOVA test (*P < 0.05). (E) Analysis of 53BP1 NBs. Cells were
either untreated or treated with 50nM CPT as indicated. Samples were subjected to immunofluorescence using anti-53BP1 and anti-Cyclin A to evaluate
53BP1 fluorescence only in G1 cells (Cyclin A-negative). Graphs show the frequency of each class of nuclei in two independent replicates. Representative
images from CPT-treated samples are shown.
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MUS81 by overexpression of the unphosphorylable S87A-
MUS81 mutant (36) in these cells could aggravate the mi-
totic defects. Interestingly, over-expression of the S87A-
MUS81mutant in wild-type cells did not affect the percent-
age of anaphase bridges and micronuclei, while it increased
the number of multinucleated cells (Figure 8A). In sharp
contrast, expression of the S87A-MUS81 mutant substan-
tially aggravated the mitotic defects in WRN exonuclease-
deficient cells (Figure 7A). Indeed, expression of the S87A-
MUS81 protein increased the number of anaphase bridges
and micronucleated cells. Similarly, expression of the S87A-
MUS81 mutant enhanced the presence of 53BP1 NBs in
WSE84A cells (Figure 8B).
To further assess the biological significance of the mi-
toticMUS81 hyperactivation observed in the absence of the
WRN exonuclease, we evaluated the sensitivity to nanomo-
lar doses of CPT by clonogenic survival. As shown in Fig-
ure 8C, WRN exonuclease-deficient cells were slightly more
sensitive to CPT then wild-type cells. Overexpression of
the wild-type MUS81 resulted in a mild increase in sen-
sitivity in wild-type cells but not in cells expressing the
exo-dead WRN (Figure 8C). In contrast, overexpression of
the S87A-MUS81 substantially increased the sensitivity of
WRN exonuclease-deficient cells to CPT (Figure 8C).
Altogether, our data indicate that the enhanced engage-
ment of RAD51 associated to loss of WRN exonuclease
requires the increased activation of the MUS81 complex
in mitosis. Therefore, expression of a MUS81 mutant that
disables mitotic activation of the MUS81/EME1 complex
increases mitotic abnormalities and sensitivity to CPT of
WRN exonuclease-deficient cells. Thus, in the absence of
theWRN exonuclease, hyperactivation of theMUS81 com-
plex functions as a fail-safe system that maintains mitotic
abnormalities at low levels, allowing survival.
DISCUSSION
In recent years, an increasing interest arose around alter-
native mechanisms of fork processing and fork degrada-
tion since they correlate to the chemosensitivity of cells
that are deficient for the primary pathway represented by
BRCA1/2-RAD51 (16,18). Most of these studies focused
on the early events occurring in the absence of BRCA1
or BRCA2, but few of them investigated mechanisms in-
volved during recovery from replication stress (33,39). Fur-
thermore, loss of BRCA1 or BRCA2 affects recombination
as well as fork protection and this prevents the investigation
of the role of recombination for the recovery of replication
forks undergoing degradation. Recently, we reported that
the WRN exonuclease activity protects against fork degra-
dation when cells are treated with clinically-relevant doses
ofCPT (12).Here, we usedWRNexonuclease-deficient cells
as a model to assess what happens at destabilized perturbed
forks when treatment with nanomolar doses of CPT is pro-
longed. We find that, in the absence of the WRN exonucle-
ase, nascent strands undergo continuous degradation that
produces accumulation of ssDNA. This late accumulation
of ssDNA follows its disappearance at early time points
because of the activities of MRE11 and EXO1 (12). In-
terestingly, the late wave of ssDNA at perturbed forks is
only minimally affected by inactivation of each single ex-
onuclease acting at perturbed forks, and is reduced only
when EXO1 is depleted or when MRE11 and DNA2 are
inhibited. While most of the degradation observed in cells
deficient of BRCA1/2 or other factors assisting RAD51
seems to involve MRE11-EXO1 (40–43), our data sug-
gest that multiple nucleases take over at forks destabilized
by the absence of WRN exonuclease with time. Treatment
with nanomolar doses of CPT does not induce DSBs un-
less treatment is prolonged (13,14). Interestingly, loss of the
WRN exonuclease makes cells resistant to the induction of
DSBs. Induction of DSBs in response to nanomolar doses
of CPT has been correlated with activation of RECQ1 pos-
sibly to promote restart of those forks that failed to be pro-
cessed otherwise (14). Loss of the ability to induce DSBs
at forks would be consistent with engagement of a distinct
fork recovery mechanism in cells expressing the exo-dead
WRN protein. Of note, RECQ1 PARylation, which reg-
ulates RECQ1 function at reversed forks after CPT (14),
is almost absent in WRN exonuclease-deficient cells (12).
The concomitant absence of RECQ1-regulatory modifica-
tion and of its consequences (i.e. DSBs) strongly support a
pathway switch at CPT-perturbed forks.
Consistent with this pathway switch, inhibition of
MRE11 in WRN exonuclease-deficient cells restores DSBs
after prolonged treatmentwith a low-dose of CPT. This sug-
gests that formation of DSBs occurs downstream of patho-
logical fork processing after takeover of other nucleases or
that the increase in nascent ssDNA observed after MRE11
inhibition in WRN exonuclease-deficient cells derives from
end-resection at DSBs. Given that each of the nucleases has
been implicated in end-resection, the former possibility is
more likely.
Interestingly, RAD51 is strongly accumulated in the ab-
sence of the WRN exonuclease and persists during recov-
ery from treatment. Of note, the enhanced recruitment of
RAD51 in chromatin parallels the reduced level of RPA.
Since binding of RPA is a pre-requisite for the binding
of RAD51, it is likely the RAD51-RPA exchange medi-
ated by BRCA2 occurs more efficiently in cells expressing
the exo-dead WRN. An elevated engagement of RAD51 in
the absence of the WRN exonuclease has been reported in
Drosophila (44), suggesting that the role of WRN exonu-
clease at perturbed forks is conserved. Similarly, unsched-
uled exonuclease-mediated processing of perturbed forks
in yeast has been recently shown to engage a RAD51-
mediated pathway (45). Furthermore, parental ssDNA, a
readout of template gaps, also accumulates in the absence
ofWRN exonuclease. RAD51 binds to ssDNAand initiates
recombination (20,30). The concomitant accumulation of
ssDNA and elevated recruitment of RAD51 in the absence
of the WRN exonuclease would be consistent with the en-
gagement of gaps left behind inactivated forks in a template-
switch mode of replication recovery, as shown after DNA
damage in Xenopus egg extracts (26). Since RAD51 and
WRN have been proposed to cooperate during recovery
from fork arrest (46), it is reasonable that loss of WRN
function also compromises the normal activity of RAD51
at fork.
Loss of WRN exonuclease results in a mild defect in
the activation of CHK1. Activation of the ATR-dependent
checkpoint requires formation of ssDNA (47–49). In the
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Figure 8. MUS81S87A mutant overexpression aggravates the mitotic phenotypes of WRN exonuclease-deficient cells. (A) Bulky bridges, multinucleated
and micro-nucleated cells were analyzed with or withoutMUS81S87A mutant overexpression, inWRNwild-type and exonuclease-deficient cells. The graph
represents the frequency of the aberration analyzed in two independent experiments± SE. (B) Analysis of 53BP1NBs formation in Cyclin A-negative cells.
Representative images of fluorescence cells stained with anti-53BP1 (green) and Cyclin A (red). Nuclear DNA was counterstained with DAPI (blue). For
each point at least 300 nuclei were counted and cells with>5 53BP1NBs were considered as positive. The graph shows the quantification of 53BP1-positive
G1 cells. (C) Clonogenic assay in cells treated with low-doses of CPT. Cells were exposed to different doses of CPT for 18h, re-plated at low density and
survival evaluated as percentages of colonises normalized against the untreated. Statistical analyses in A-C were performed by ANOVA test (*P < 0.05;
** P < 0.01).
absence of the WRN exonuclease ssDNA accumulates
but is hijacked by RAD51 and it is not completely free
for the binding of checkpoint factors. Indeed, in WRN
exonuclease-deficient cells, TopBP1 and its binding fac-
tor RAD9 are not more highly associated with ssDNA as
compared with the wild-type. Notably, phosphorylation of
ATR, a readout of its activation, is indistinguishable from
the wild-type. It suggests that ATR also gets activated in-
dependently from ssDNA. Alternatively, a hyperactivation
of ATR could be prevented by RAD51 through sequester-
ing of ssDNA. Indeed, overexpression of RAD51 has been
shown to affect checkpoint activation (50). Thus, CHK1
phosphorylation is probably dampened because of a faster
ormore efficient RPA-RAD51 exchange that also correlates
to reduced recruitment of RAD9 and TopBP1. Notably,
bypassing of the CHK1 activation defect by expression of
a phosphomimetic CHK1 mutant in WRN exonuclease-
deficient cells restores normal levels of ssDNA. This sug-
gests that accumulation of ssDNA is also unleashed by re-
duced CHK1 activation through a positive feedback loop.
The observed elevated recruitment of RAD51, which is
used during recovery in the absence of the WRN exonucle-
ase to deal with under-replicated DNA, also leads to ele-
vated phosphorylation of MUS81 at S87. Phosphorylation
of MUS81 at S87 occurs in G2/M and is related to resolu-
tion of recombination intermediates (36). Consistently, in-
hibition of RAD51 reduces S87 phosphorylation in WRN
exonuclease-deficient cells. Thus, engagement of RAD51-
dependent fork recovery, possibly by template switching at
parental gaps, results in an increased number of interlinked
intermediates calling for resolution by the MUS81 com-
plex. Our data indicate that activation of MUS81 complex
in G2/M is essential to overcome segregation defects aris-
ing from excessive RAD51-dependent recombination and
support proliferation upon treatment with CPT. Indeed, ex-
pression of the unphosphorylable S87A-MUS81mutant in-
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Figure 9. Proposed model of the effect of prolonged treatment with nanomolar CPT doses in absence of WRN exonuclease (see text for details).
creases abnormal mitosis and sensitizes WRN exonuclease-
deficient cells.
Loss of the WRN exonuclease, although resulting in fork
degradation, does not induceMUS81 activation in S-phase,
which is observed in the absence of BRCA2 (42). However,
the persistence of under-replicated DNA and requirement
of MUS81 complex activity in G2/M also characteristic of
BRCA2-deficient cells (39). Thus, it is tempting to specu-
late that elevated fork degradation correlates with inabil-
ity to replicate all the genome. Notably, BRCA2-deficient
cells show much more severe mitotic defects (33,39). In
WRN exonuclease-deficient cells, mitotic abnormalities are
increased by disabling MUS81 function in mitosis but are
likely increased also by impairing RAD51 function during
recovery, since RAD51 inhibition results in increased accu-
mulation of parental ssDNA and induces a significant mi-
totic block. As BRCA2 deficiency also interferes with the
post-replicative function of RAD51 (26) it is tempting to
speculate that the elevated mitotic defects might be the end-
result of combined fork deprotection and recombination
defects. Indeed, it has been recently demonstrated that mi-
totic abnormalities in BRCA2-deficient cells are primarily
linked to loss of the recombination function ofRAD51 (33).
Collectively, our data show that WRN exonuclease-
deficient cells can be a useful model to investigate the fate
of deprotected or destabilized replication forks under a
clinically-relevant, specific type of replication stress; and,
togetherwith published data, they can be summarized in the
model shown in Figure 9. In response to nanomolar CPT,
perturbed replication forks rapidly undergo fork reversal
(13). In wild-type cells, with time, reversed forks degener-
ate into DSBs, possibly because of unscheduled RECQ1-
mediated fork restoration (14). In the absence of WRN ex-
onuclease, perturbed replication forks undergo a further cy-
cle of degradation of nascent strand by MRE11 and/or
DNA2, which leads to ssDNA accumulation and engage-
ment of RAD51. The WRN exonuclease activity might be
required to clear stalled Okazaki fragments by promoting
their 3’-5’ degradation or to remove D-loop intermediates
(51). In the first case, replication fork reversal might be re-
strained also avoiding excessive, post-reversal, degradation
of the nascent strands. In the second case, unscheduled en-
gagement of recombination either from reversed forks or
stalled forks might be prevented. Since the two possibili-
ties are not mutually-exclusive, the elevated engagement of
recombination seen in the absence of WRN exonuclease
may result from a complex phenotype. The accumulation
of ssDNA and possibly engagement of RAD51 make per-
turbed replication forks resistant toDSBs and interfere with
checkpoint signaling, resulting in a mild defect in CHK1
activation. In the absence of WRN exonuclease, more per-
turbed forks become inactivated over-time and RAD51 is
required also during recovery from CPT to support repair
at template gaps left behind the inactive forks. In WRN
exonuclease-deficient cells, engagement of RAD51 during
recovery stimulates activation of the MUS81 complex in
G2/M and limit mitotic defects and cell death as also oc-
cur at difficult-to-replicate regions (52).
AsCPT is a chemotherapeutic, our data also indicate that
tumors with impaired function of the WRN exonuclease
can be sensitized to treatment by genetic or chemical inter-
ference with the MUS81 complex in mitosis, which is less
relevant for survival in cells expressing the WRNwild-type.
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